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Abstract: 
Background:Research has begun to uncover the likely role of melatonin in primary headache disorders 
such as migraine. The pineal gland produces the hormone melatonin and is largely influenced by 
environmental stimuli.Migraines often have environmental triggers with research starting to show lower 
levels of circulating melatonin found in migraineurs. Melatonin is an inexpensive, easily procured, and 
natural hormone with a minimal side effect profile compared to current pharmacologic migraine 
treatments. It is thought that migraine treatment with melatonin can decrease migraine occurrence, 
severity, and duration. 
Methods: Exhaustive search of available medical literature was conducted on MEDLINE-PubMed, Clinical 
Key, CINAHL-EBSCO host using the keywords: melatonin and migraine. Inclusion criteria consisted of 
studies on the adult population, using immediate release melatonin, and on patients with classic 
migraines with and without aura. Quality assessment was conducted using GRADE. 
Results: The search resulted in two studies. When comparing from baseline to month 3 of treatment with 
melatonin, a greater than 50% reduction in headache frequency was seen in 53% (32/60) of patients in 
one study and 78% (25/32) of patients in the other study.. Reduction of migraine frequency (in migraine 
days) was 2.7 and 4.6 fewer days per month, respectively. Reduction in migraine intensity (0-10 scale) 
was 3.5 and 3.8, respectively. Reduction in migraine duration per episode was 7.2 and 11 hours, 
respectively. All reductions were observed comparing baseline to month 3 of treatment with melatonin. 
Conclusion: Prophylactic use of 3mg of melatonin daily for migraine prevention and symptom reduction 
was found to significantly reduce frequency, intensity, and duration of attacks when comparing patients 
baseline and after 3 months of treatment. 
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Abstract  
Background: Research has begun to uncover the likely role of melatonin in primary headache 
disorders such as migraine. The pineal gland produces the hormone melatonin and is largely 
influenced by environmental stimuli. Migraines often have environmental triggers with research 
starting to show lower levels of circulating melatonin found in migraineurs. Melatonin is an 
inexpensive, easily procured, and natural hormone with a minimal side effect profile compared 
to current pharmacologic migraine treatments. It is thought that migraine treatment with 
melatonin can decrease migraine occurrence, severity, and duration.  
Methods:  Exhaustive search of available medical literature was conducted on MEDLINE-
PubMed, Clinical Key, CINAHL-EBSCO host using the keywords: melatonin and migraine. 
Inclusion criteria consisted of studies on the adult population, using immediate release 
melatonin, and on patients with classic migraines with and without aura. Quality assessment was 
conducted using GRADE.  
Results:  The search resulted in two studies. When comparing from baseline to month 3 of 
treatment with melatonin, a greater than 50% reduction in headache frequency was seen in 53% 
(32/60) of patients in one study and 78% (25/32) of patients in the other study.. Reduction of 
migraine frequency (in migraine days) was 2.7 and 4.6 fewer days per month, respectively. 
Reduction in migraine intensity (0-10 scale) was 3.5 and 3.8, respectively. Reduction in migraine 
duration per episode was 7.2 and 11 hours, respectively. All reductions were observed comparing 
baseline to month 3 of treatment with melatonin.  
Conclusion: Prophylactic use of 3mg of melatonin daily for migraine prevention and symptom 
reduction was found to significantly reduce frequency, intensity, and duration of attacks when 
comparing patients baseline and after 3 months of treatment.  
Keywords:  Melatonin, prophylaxis, migraine. 
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Prophylactic use of Immediate Release Melatonin for Decreasing Occurrence, Severity, and 
Duration of Migraines in the Adult Population 
 
BACKGROUND 
 Roughly 24 million individuals in the US suffer from migraine headaches.1 Of those 
seeking treatment only 3-5% report adequate preventative therapy while roughly half stop 
seeking care due to dissatisfaction.2 Further research on migraine causation and novel treatment 
options are needed for this majority of patients receiving what they view as inadequate care. 
Though current treatment has been shown to provide symptomatic relief, the side effect profile 
of such medications often impede treatment adherence. A correlation between the pineal gland 
and migraines has been hypothesized due to a congruency of environmentally triggered 
melatonin release from the pineal gland from similar causative/exacerbative stimuli on migraine 
symptomotology.3 Melatonin has been shown to be well tolerated even at high doses with a mild 
to no side effect profile in patients.4 Evidence for the use of melatonin to treat migraine has been 
increasing.  
 Several avenues pointed towards the exploration of melatonin as a factor in primary 
headaches. Melatonin release is directly influenced by environmental factors. Best known of 
these factors is light (photo) stimulation on the eyes. As Joel J. Gagnier described in his study,5-6 
the pineal gland is considered a photoendocrine transducer, translating information from the 
environment to directly influence the amount of melatonin released. In addition, the 
suprachiasmatic nucleus (SCN) releases N-Acetyltransferase which synthesizes melatonin from 
serotonin based on photic-stimulation by the environment.6 Thus a possible link may exist 
between light stimulation on the eye and decreased melatonin release from the pineal gland 
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leading to worsening migraine symptoms. Additionally, smell, temperature, and noise influence 
both melatonin release and the worsening of migraines.5 
 There are numerous studies that have explored serotonin, the SCN, and melatonin in 
relation to migraines. In one study,7 migraine symptoms were found to alleviate in patients given 
serotonin and serotonin derivatives with symptoms made worse by serotonin synthesis 
inhibitors.7 It is also worth mentioning there is increased concurrence of migraines and 
depression which likely has something to do with decreased serotonin. Three studies6, 8-9 looking 
at menstrual linked migraines found significant evidence for decreased urine melatonin levels in 
migraneurs as compared to control populations. An even greater decrease in urine melatonin 
levels was found in those experiencing acute migraine attacks., 8-9 Observational studies10 found 
that migraneurs have lower melatonin levels on migraine days compared to symptom free days. 
Those suffering from chronic migraines were found to have lower melatonin levels compared to 
episodic migraine sufferers.10 Two studies11-12 evaluated prolonged release melatonin of  2 and 
4mg from the medication Circadin. Both studies used headache frequency as their primary 
outcome when comparing melatonin treatment to non-treatment baseline. The study utilizing 
2mg of Circadin found no significant decrease in number of headaches compared to placebo. 
However, the study using 4mg Circadin did find a significant decrease in headache days per 
month of the study. It is worth noting that the study with 2mg of medication was double-blind 
placebo controlled while the study using 4mg was a double-blind cross-over pilot study. 
 Though evidence supports the role of melatonin in migraines, the mechanism of action is 
not fully understood and likely multifaceted. Melatonin has been known to increase sleep 
hygiene, have anxiolytic and analgesic properties, inhibit nitrous oxide production, and has 
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strong antioxidant characteristics.13 Cerebral vasodilation has been thought to be a factor in 
migraine causation. Melatonin inhibition of nitrous oxide may help to prevent cerebral 
vasodilation. Melatonin has several analgesic mechanisms. Svogler et al goes on to describe 
melatonin as structurally similar to the NSAID indomethacin. Further, like indomethacin, 
melatonin has anti-inflammatory properties by inhibiting prostaglandin E that mainly targets the 
trigeminovascular system. It also inhibits up-regulation of pro-inflammatory cytokines. Evidence 
also suggests that melatonin potentiates opioid and GABA receptors increasing analgesic 
response.13  
METHODS 
 A systematic search of electronic databases was conducted utilizing MEDLINE-Pubmed, 
CINAHL-EBSCOhost, and Clinicalkey. The search strategy involved a methodological filter for 
abstract and full text human trial studies. Subject specific terms were limited to migraines and 
melatonin. Studies with a close match for migraines and treatment with melatonin were used to 
further find sources out of the reference section. Exclusion criteria was used to refine the myriad 
of studies returned pertaining to migraines and prophylactic treatment with melatonin. Criteria 
was used to select studies pertaining to the adult population between 18 and 65 years, males and 
females suffering from migraines with and without auras, and use of immediate release 
melatonin. Exclusion was applied to studies using prolonged release melatonin (Circadin), 
studies looking only at menstrual migraines, studies that included other primary headaches like 
tension and cluster, and studies looking specifically at the pediatric population. Quality 
assessment of the studies was conducted using GRADE. Inconsistency, indirectness, bias, and 
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imprecision was analyzed. The studies were rated low in GRADE quality as referenced at 
http://www.gradeworkinggroup.org. 
RESULTS 
 The search yielded 371 articles.  Applying eligibility criteria yielded two studies with 
similar design: Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and 
placebo for migraine prevention, by Leite Goncalves et al,14 and Melatonin, 3 mg, is effective for 
migraine prevention, by Peres et al.15 (See Table 1.) Both of the studies14-15 used a nearly 
identical design with similar end points. The study by Goncalves et al14 included a placebo and 
amitriptyline group in addition to the melatonin treatment group. Peres et al15 only used a 
melatonin treatment group. Thus only the melatonin treatment group in each study was analyzed. 
Both studies14-15 occurred over 4 months with a month long baseline period. Migraine frequency, 
intensity (1-10), and duration were recorded for each month resulting in data points for: baseline, 
month 1, month 2, and month 3. Of these data points, only baseline, month 1, and month 3 were 
analyzed in this review. Primary endpoint analyzed for each study was the percentage of patients 
that experience a greater than 50% reduction in migraine frequency when comparing baseline to 
month 3 of treatment.  
 Melatonin treatment data between the two studies was evaluated (see table 2) looking at 
the progression of three migraine factors over the course of 3 months for both studies (baseline, 
month 1, and month 3). Ninety-two patients were used in the analysis, 60 patients from 
Goncalves et al. and 32 from Peres et al. Patients experiencing a greater than 50% reduction 
between the two studies totaled 57/92 for 62% between the two studies. For the study of 
Goncalves et al., an average reduction in frequency of migraines (7.3 at baseline, 5.6 at month 1, 
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4.6 at month 3), intensity on a 0-10 scale (7.1 at baseline, 5.0 at month 1, 3.6 at month 3), and 
migraine length in hours (18.1 at baseline, 13.5 at month 1, 7.2 at month 3) was seen between 
baseline, month 1, and month 3 for both studies (see table 2). Similar results were seen in the 
study by Peres et al. with an average reduction in frequency of migraines (7.6 at baseline, 4.4 at 
month 1, 3.0 at month 3), intensity on a 0-10 scale (7.4 at baseline, 5.5 at month 1, 3.6 at month 
3), and migraine length in hours (19.8 at baseline, 10.2 at month 1, 8.8 at month 3) was seen 
between baseline, month 1, and month 3 (see table 2). 
DISCUSSION 
 The results of this review support the findings of both individual studies14-15 being 
analyzed. A significant decrease in frequency, severity, and length of migraine was observed by 
the first month of prophylactic treatment with 3mg of immediate release melatonin. Both studies 
had a significant primary endpoint finding with 78.1% of Peres et al patients compared to the 
54.4% Goncalves et al patients experienced greater than a 50% reduction in migraine frequency 
by 3 months.  
 One of the most interesting findings is found in the study by Goncalves et al14 where 3mg 
melatonin is seen just as effective in treating migraines as amitriptyline 25mg. In fact number 
needed to treat was 3 with a relative risk of 2.67 and ARR of 34%. This suggests that melatonin 
may be as efficacious in treating migraines as a leading migraine medication with many patients 
receiving therapeutic benefit. This also highlights the benefits of treatment with melatonin 
compared to other leading migraine medications. Melatonin is very well tolerated with the adult 
and pediatric population while being extremely difficult to overdose on and inexpensive to 
obtain. This could likely increase patient satisfaction with treatment of their migraines and 
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decrease the number of those who have given up on seeking further treatment due to negative 
treatment side-effects.  
 There are limitations to this research. The primary author of Melatonin, 3 mg, is effective 
for migraine prevention, Dr. M.F.P. Peres, is also the sixth listed author for the other study, 
Randomised clinical trial comparing melatonin 3mg, amitriptaline 25 mg and placebo for 
migraine prevention, analyzed in this paper. It is possible that the initial study14 was a pilot study 
leading directly to the second study15 by the lead author Goncalves. A bias may exist due to this 
collaboration. The pilot study by Peres et al15 is an underpowered study that also lacks a placebo 
arm. The Peres et al study15 population reported higher baseline values and noticeably lower 
month 1 and 3 values compared to the Goncalves et al study14 population. This may partially be 
due to the fact that the Peres et al participants knew they were getting the study medication. 
 Research on melatonin and its role in migraines has been well documented and 
hypothesized for many years with research devoted to the topic going back more than 30 years. 
Evidence suggests the strong prophylactic nature of melatonin in preventing and diminishing the 
severity of primary headaches in a variety of patients but more studies are needed especially 
studies with a larger patient population that utilizes a randomized controlled double-blind design.  
CONCLUSION 
 Prophylactic use of 3mg melatonin daily for migraine prevention and symptom reduction 
was found to significantly reduce frequency, intensity, and duration of attacks when comparing 
patients baseline and after 3 months of treatment. Of primary importance is the greater than 50% 
reduction in frequency of migraine attacks observed by 78.1% of Peres et al patients compared to 
the 54.4% Goncalves et al patients by the end of 3 months. More research is needed, but 
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preliminary findings are promising. Melatonin may be as effective as amytriptaline, one of the 
leading treatment options. In addition, it is safe, cheap, easily obtained, and easy to initiate. Most 
importantly, it can safely be used in conjunction with other treatment options.  
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number of 
studies 
 
 
Study Designs 
Downgrade 
Criteria 
Upgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
 
Migraine 
frequency 
2 RCT, 
Observational 
Study 
Seriousa Not Serious Not Serious Seriousb Likelyc Low 
Migraine 
Severity 
2 RCT, 
Observational 
study 
Seriousa Not Serious Not Serious Seriousb Likelyc Low 
Migraine 
Duration 
2 RCT, 
Observational 
Study 
Seriousa Not serious Not serious  serious b Likelyc Low 
a Lack of blinding of both data collectors and patients in Peres et al study.15 
b Small sample size 
c There are multiple authors that are part of both studies being used.  
 
 
Table 2: Summary of Findings 
 Baseline Month 1 Month 3 
Frequency 
(days/month) 
7.3 
7.6* 
5.6 
4.4* 
4.6 
3.0* 
Severity (1-10) 7.1 
7.4* 
5.0 
5.5* 
3.6 
3.6* 
Duration (hrs) 18.1 
19.8* 
13.5 
10.2* 
10.9 
8.8* 
Goncalves et al. 
Peres et al.* 
 
